Literature DB >> 7326194

Lower relapse rates after neighbourhood injection of Corynebacterium parvum in operable cervix carcinoma.

M H Mignot, J W Lens, H A Drexhage, B M von Blomberg, V D Flier, J Oort, J G Stolk.   

Abstract

The effect of adjuvant immunotherapy with a single neighbourhood injection of 2 mg C. parvum (CP) was investigated in a randomized study involving 43 patients with carcinoma of the cervix uteri, all of whom were treated by radical surgery. All patients had carcinoma confined to the cervix, the upper part of the vagina or the parametrial region. When the malignancy had spread to the parametrial region, additional postoperative radiotherapy was given. 22 patients received immunotherapy 10 days before surgery, whereas the remaining 21 control patients received no immune stimulation. Only minor side effects of CP were encountered. Follow-up shows a relapse rate of 5% in the CP treated group and of 29% in the controls (P less than 0.05). A further 15 patients with more advanced malignancies were added to our studies. In these, CP stimulation had no effect on relapse rates, but the relapse-free intervals were longer after immune stimulation: control 3.5 months (mean) +/- 1.5 (s.d.), CP 13.0 months +/- 7.0 (P less than 0.05). The number of peripheral T cells and the ability to become sensitized to DNCB were increased after CP stimulation. A decrease was found in the number of blood monocytes and the number of monocytes capable of transforming into active macrophages, indicating a possible sequestration of these cells in the tissues.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7326194      PMCID: PMC2010856          DOI: 10.1038/bjc.1981.284

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  23 in total

1.  The effect of Corynebacterium parvum on the humoral and cellular immune systems in patients with breast cancer.

Authors:  J P Minton; J L Rossio; B Dixon; M C Dodd
Journal:  Clin Exp Immunol       Date:  1976-06       Impact factor: 4.330

2.  Studies on the mechanism of immunological enhancement of tumor homografts. III. Interaction between humoral isoantibodies and immune lymphoid cells.

Authors:  G MOLLER
Journal:  J Natl Cancer Inst       Date:  1963-06       Impact factor: 13.506

3.  Biological effects of the adjuvant Corynebacterium parvum. II. Evidence for macrophage-T-cell interaction.

Authors:  M T Scott
Journal:  Cell Immunol       Date:  1972-11       Impact factor: 4.868

4.  Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes.

Authors:  E Engvall; P Perlmann
Journal:  J Immunol       Date:  1972-07       Impact factor: 5.422

5.  Abnormal monocyte chemotactic response in cancer patients.

Authors:  D A Boetcher; E J Leonard
Journal:  J Natl Cancer Inst       Date:  1974-04       Impact factor: 13.506

6.  Defective monocyte function in patients with genitourinary carcinoma.

Authors:  M S Hausman; S Brosman; R Snyderman; M R Mickey; J Fahey
Journal:  J Natl Cancer Inst       Date:  1975-11       Impact factor: 13.506

7.  Suppression of cellular immunity by anesthesia and operation.

Authors:  J L Tarpley; P L Twomey; W J Catalona; P B Chretien
Journal:  J Surg Res       Date:  1977-03       Impact factor: 2.192

8.  Monocytes and macrophages in malignant melanoma. I. Peripheral blood macrophage precursors.

Authors:  G A Currie; D W Hedley
Journal:  Br J Cancer       Date:  1977-07       Impact factor: 7.640

9.  Humoral and cell-mediated immune response in patients with malignant melanoma. I. In vitro lymphocyte reactivity to PHA and antigens following immunization.

Authors:  G C de Gast; T H The; H Schraffordt Koops; H A Huiges; J Oldhoff; H O Nieweg
Journal:  Cancer       Date:  1975-10       Impact factor: 6.860

10.  Thymus-derived rosette-forming cells in various human disease states: cancer, lymphoma, bacterial and viral infections, and other diseases.

Authors:  J Wybran; H H Fudenberg
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

View more
  3 in total

1.  Experimental screening of BCG preparations produced for cancer immunotherapy: safety and immunostimulating and antitumor activity of four consecutively produced batches.

Authors:  W H de Jong; P A Steerenberg; J G Kreeftenberg; R H Tiesjema; W Kruizinga; L M van Noorle Jansen; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

2.  Morphology of draining lymph nodes after local immune stimulation with C. parvum: comparison of pelvic nodes in carcinoma of cervix and popliteal and inguinal nodes of guinea-pig.

Authors:  M H Mignot; J W Lens; J G Stolk; J Oort; R W Veldhuizen; G H Dijkhuizen; H A Drexhage
Journal:  Br J Cancer       Date:  1982-08       Impact factor: 7.640

Review 3.  Efficacy and Safety of Immunotherapy for Cervical Cancer-A Systematic Review of Clinical Trials.

Authors:  Mona W Schmidt; Marco J Battista; Marcus Schmidt; Monique Garcia; Timo Siepmann; Annette Hasenburg; Katharina Anic
Journal:  Cancers (Basel)       Date:  2022-01-17       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.